Clinically relevant drug–drug interactions between antiretrovirals and antifungals
Authors:
- 11 February 2014
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 10 (4) , 561-580
Abstract
(2014). Clinically relevant drug–drug interactions between antiretrovirals and antifungals. Expert Opinion on Drug Metabolism & Toxicology: Vol. 10, No. 4, pp. 561-580.Keywords
This publication has 89 references indexed in Scilit:
- The structural biology of HIV-1: mechanistic and therapeutic insightsNature Reviews Microbiology, 2012
- Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretroviralsLife Sciences, 2011
- Temporal Trends in Presentation for Outpatient HIV Medical Care 2000–2010: Implications for Short-term MortalityJournal of General Internal Medicine, 2011
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Fungal echinocandin resistanceFungal Genetics and Biology, 2010
- Maraviroc:in vitroassessment of drug–drug interaction potentialBritish Journal of Clinical Pharmacology, 2008
- Pharmacokinetics of darunavir/ritonavir and ketoconazole following co‐administration in HIV–healthy volunteersBritish Journal of Clinical Pharmacology, 2008
- Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteersBritish Journal of Clinical Pharmacology, 2008
- Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteersBritish Journal of Clinical Pharmacology, 2008
- Steady-State Pharmacokinetic and Safety Profiles of Voriconazole and Ritonavir in Healthy Male SubjectsAntimicrobial Agents and Chemotherapy, 2007